PriceTargets.com logo

Nexalin Technology - NXL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: -28.91%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.22 As of 11/15/2024 01:00 AM ET
▲ +0.12 (2.93%)

This chart shows the closing price for NXL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nexalin Technology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NXL

Analyst Price Target is $3.00
▼ -28.91% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Nexalin Technology in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a -28.91% upside from the last price of $4.22.

This chart shows the closing price for NXL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Nexalin Technology.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/9/2024Maxim GroupInitiated CoverageBuy$3.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Nexalin Technology logo
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Read More

Today's Range

Now: $4.22
Low: $3.80
High: $4.30

50 Day Range

MA: $1.59
Low: $0.62
High: $4.22

52 Week Range

Now: $4.22
Low: $0.25
High: $4.36

Volume

989,098 shs

Average Volume

4,346,881 shs

Market Capitalization

$54.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Nexalin Technology?

The following equities research analysts have issued research reports on Nexalin Technology in the last year: Maxim Group.
View the latest analyst ratings for NXL.

What is the current price target for Nexalin Technology?

0 Wall Street analysts have set twelve-month price targets for Nexalin Technology in the last year. Their average twelve-month price target is $3.00, suggesting a possible downside of 28.9%. Maxim Group has the highest price target set, predicting NXL will reach $3.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Nexalin Technology in the next year.
View the latest price targets for NXL.

What is the current consensus analyst rating for Nexalin Technology?

Nexalin Technology currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NXL will outperform the market and that investors should add to their positions of Nexalin Technology.
View the latest ratings for NXL.

What other companies compete with Nexalin Technology?

Other companies that are similar to Nexalin Technology include Alpha Tau Medical, Lakeland Industries, KORU Medical Systems, TriSalus Life Sciences and Sonendo. Learn More about companies similar to Nexalin Technology.

How do I contact Nexalin Technology's investor relations team?

The company's listed phone number is 832-260-0222 and its investor relations email address is [email protected]. The official website for Nexalin Technology is www.nexalin.com. Learn More about contacing Nexalin Technology investor relations.